CO.DON AG: CO.DON AG and JOINT OPERATIONS (UK) LLP sign contract for the distribution of Spherox in United Kingdom

Teltow (pta016/21.03.2022/10:00 UTC+1)

Teltow / Leipzig, 21 March 2022 – CO.DON AG and JOINT OPERATIONS (UK) LLP signed an exclusive agreement to distribute the EU-authorised, cell-based medicinal product Spherox in the United Kingdom, including Scotland, Wales and Northern Ireland. The contract is initially for three years and defines minimum order quantities. CO.DON AG will support JOINT OPERATIONS (UK) LLP throughout the entire distribution period and retains defined responsibilities.

Tilmann Bur, CEO of CO.DON AG, was very pleased with the conclusion of the successful negotiations, "We are delighted that we and JOINT OPERATIONS have been able to sign a contract that is highly productive for both parties. Britain was the first EU country outside our home market where we sold our product after it was authorised – initially on our own via a subsidiary. Now the aim is to achieve greater market penetration, and we are confident that with JOINT OPERATIONS we have found the right partner for doing so. They have a strong sales team for one thing, which is 100% dedicated to regenerative treatments. As a human tissue bank and specialist for regenerative medicine, JOINT OPERATIONS has long-standing, reliable contacts to decision-makers in the national market, which would also help us for any expansion of our product portfolio."

Richard Forster, Managing Director JOINT OPERATIONS (UK) LLP: "JOINT OPERATIONS is focused on helping patients avoid a premature joint replacement by providing clinicians with the tools to treat damaged cartilage, meniscus, ligaments and alignment through surgical and non-surgical care. To achieve this, we work with the leading R&D and manufacturing companies in the field and are proud and excited to add CO.DON as a new partner. Spherox is a unique cartilage technology approved for use by the UK’s National Institute for Clinical Excellence (NICE) as a result of its excellent record of safety and efficacy."

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 17,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product, followed by the marketing authorization for Switzerland in March 2019. At the Leipzig site, CO.DON has built one of the largest facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A3E5C08). Executive Board: Tilmann Bur.

Further information is available from www.codon.de.

Contact

Matthias Meißner
Director Corporate Communications

Investor Relations / Public Relations
T: +49 (0)341 99190 330
F: +49 (0)341 99190 309
E: ir@codon.de

(end)

Emitter:	CO.DON AG Warthestraße 21 14513 Teltow Germany
Contact Person:	Matthias Meißner
Phone:	+49 341 99190330
E-Mail:	ir@codon.de
Website:	www.codon.de
ISIN(s):	DE000A3E5C08 (Share) DE000A3E5C16 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate